{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:26:02Z","timestamp":1793805962227,"version":"4.6.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.urolonc.2026.06.018","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T05:50:25Z","timestamp":1783921825000},"page":"497-504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of number of bone metastases on cancer control outcomes in mHSPC, independent of the axial-skeleton CHAARTED definition"],"prefix":"10.1016","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4338-0889","authenticated-orcid":false,"given":"Mike","family":"Wenzel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Theissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Siech","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Lauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Filzmayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Humke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Kriegmair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Steuber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix K.H.","family":"Chun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Mandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2026.06.018_bib0001","unstructured":"Cornford P, Tilki D, van den Bergh RCN, et al. EAU guidelines on prostate cancer. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978\u201394\u201392671\u201323\u20133."},{"key":"10.1016\/j.urolonc.2026.06.018_bib0002","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.euros.2024.06.010","article-title":"Contemporary treatment patterns and oncological outcomes of metastatic hormone-sensitive prostate cancer and first- to sixth- line metastatic castration-resistant prostate cancer patients","volume":"66","author":"Wenzel","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urolonc.2026.06.018_bib0003","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1016\/S0140-6736(24)00651-2","article-title":"The Lancet comission on prostate cancer: planning for the surge in cases","volume":"403","author":"James","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2026.06.018_bib0004","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.eururo.2023.11.018","article-title":"Prostate-specific membrane antigen-targeted therapies for prostate cancer: towards improving therapeutic outcomes","volume":"85","author":"Corpetti","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2026.06.018_bib0005","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal theraoy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"New Engl J Med"},{"issue":"2","key":"10.1016\/j.urolonc.2026.06.018_bib0006","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.euf.2021.04.003","article-title":"Overall survival after systemic treatment in high-volume versus low-volume metastatic hormone-sensitive prostate cancer: systematic review and network meta-analysis","volume":"8","author":"Wenzel","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2026.06.018_bib0007","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.06.018_bib0008","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.eururo.2018.02.001","article-title":"Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies","volume":"73","author":"Gravis","year":"2018","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.06.018_bib0009","doi-asserted-by":"crossref","first-page":"397.e9","DOI":"10.1016\/j.urolonc.2025.01.001","article-title":"Association between frailty and specific comorbidities on oncological outcomes in metastatic hormone-sensitive and castration resistant prostate cancer","volume":"43","author":"Wenzel","year":"2025","journal-title":"Urol Oncol"},{"issue":"20","key":"10.1016\/j.urolonc.2026.06.018_bib0010","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.3390\/cancers16203506","article-title":"Assessment of different castration resistance definitions and staging modalities in metastatic castration-resistant prostate cancer","volume":"16","author":"Wenzel","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.urolonc.2026.06.018_bib0011","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.eururo.2023.04.002","article-title":"The efficacy of enzalutamide plus androgen deprivation therapy in oligometastatic hormone-sensitive prostate cancer: a post hoc analysis of ARCHES","volume":"84","author":"Armstrong","year":"2023","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2026.06.018_bib0012","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.euo.2025.07.002","article-title":"Apalutamide in patients with high burden of metastatic hormone-sensitive prostate cancer: a subgroup analysis of TITAN","volume":"8","author":"Rodriguez-Vida","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.06.018_bib0013","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.euo.2020.07.001","article-title":"Patterns of cancer progression of metastatic hormone-sensitive prostate cancer in the ECOG3805 CHAARTED trial","volume":"3","author":"Bryce","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.06.018_bib0014","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","author":"Francini","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2026.06.018_bib0015","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2026.06.018_bib0016","first-page":"376","article-title":"Seven-month prostate-specific antigen is prognostic in metastatic hormone-sensitive prostate cancer treated with androgen deprivation with or without docetaxel","volume":"36","author":"Harshman","year":"2018","journal-title":"Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.06.018_bib0017","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamid and survival in metastatic homone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engk J Med"},{"issue":"20","key":"10.1016\/j.urolonc.2026.06.018_bib0018","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and Docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2026.06.018_bib0019","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1002\/pros.24016","article-title":"Prognostic factors influencing overall survival in de novo oligometastatic prostate cancer patients","volume":"80","author":"Rij","year":"2020","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2026.06.018_bib0020","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/pros.23958","article-title":"How many bone metastases may be defined as high-volume metastatic prostate cancer in Asians: a retrospective multicenter cohort study","volume":"0","author":"Yamada","year":"2020","journal-title":"Prostate"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.018_bib0021","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1186\/s12885-026-15803-y","article-title":"Cancer-control outcomes of patients with metastatic hormone-sensitive prostate cancer and \u2265\u200910 bone metastases receiving apalutamide: a real-world cohort","volume":"26","author":"Wenzel","year":"2026","journal-title":"BMC Cancer"},{"key":"10.1016\/j.urolonc.2026.06.018_bib0022","doi-asserted-by":"crossref","first-page":"e14615","DOI":"10.7717\/peerj.14615","article-title":"Development and validation of a novel risk model in newly diagnosed de novo bone metastatic prostate cancer (M1b): a retrospective study","volume":"11","author":"Zhang","year":"2023","journal-title":"PeerJ"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:28:15Z","timestamp":1793802495000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1078143926005764"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.018","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of number of bone metastases on cancer control outcomes in mHSPC, independent of the axial-skeleton CHAARTED definition","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}